PT - JOURNAL ARTICLE AU - Heiberg, Adam Vittrup AU - Lukassen, Troels Gil AU - Truelsen, Thomas Clement AU - Borgwardt, Henrik Gutte AU - Benndorf, Goetz AU - Sølling, Christine AU - Schytz, Henrik Winther AU - Møller, Kirsten AU - Hansen, Klaus AU - Iversen, Helle Klingenberg TI - Dynamic cerebral autoregulation during and 3 months after endovascular treatment in large-vessel occlusion stroke AID - 10.1101/2024.09.05.24313166 DP - 2024 Jan 01 TA - medRxiv PG - 2024.09.05.24313166 4099 - http://medrxiv.org/content/early/2024/09/07/2024.09.05.24313166.short 4100 - http://medrxiv.org/content/early/2024/09/07/2024.09.05.24313166.full AB - Background Acute ischemic stroke caused by large-vessel occlusion is effectively treated by endovascular treatment (EVT). However, treatment could be further refined by improved understanding of the underlying pathophysiology, including dynamic cerebral autoregulation (dCA). Near-infrared spectroscopy (NIRS) requires virtually no setup time and enables dCA investigation during EVT by measuring dynamic concentration in cortical oxygenated hemoglobin (OxyHb) continuously.Methods The aim was to investigate dCA during EVT, before and after recanalization, and at follow-up after 24 hours and 90 days. We applied interhemispheric transfer function analysis of low-frequency (LF) oscillations (0.07-0.2 Hz) in OxyHb that yields the dCA measures, gain and phase shift. Mixed-effect models were used to examine dCA over time. We then predicted outcome by dCA in multivariate logistic regression models.Results We found higher LF gain in patients with favorable outcome. While dCA was stable for most patients during EVT, LF phase shift increased immediately after recanalization for patients with milder symptom severity and at 24-hour follow-up for patients with more severe symptoms. Adjusted for age, infarct size before EVT, and recanalization success, average LF gain predicted independent functional outcome, symptom severity and mortality at 90-day follow-up.Conclusions Interhemispheric transfer function analysis based on NIRS provides insights into dCA changes during EVT that could potentially be applied in the development of individualized treatment. The method relies on intact contralateral dCA which needs further investigations. The potential of dCA to strengthen prediction models also warrant additional examination.Clinical Trial Registration ClinicalTrial.gov: NCT03738644. https://clinicaltrials.gov/study/NCT03738644.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov: NCT03738644Funding StatementThe study was supported by Simon Fougner Hartmanns Family Foundation, Gangsted Foundation, Sophus Jacobsen Foundation and Rigshospitalet?s Research Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Scientific Ethics Committees for the Capital Region of Denmark (H-18028704)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesABPArterial Blood PressureACAAnterior Cerebral ArteryAISAcute Ischemic StrokeASPECTSAlberta Stroke Program Early CT ScoreBABasilar artery.CW-NIRSContinuous Wave Near-Infrared SpectroscopydCADynamic Cerebral AutoregulationDeoxyHbDeoxygenated Hemoglobin ConcentrationEVTEndovascular TreatmentFUFollow-upFU24-groupAll participants with sufficient data at PRE, POST and 24-hour FU.FU90-groupAll patients with sufficient data at PRE, POST, 24-hour and 90-day FU.HFHigh-frequency (0.2-0.5 Hz)ICAInternal carotid artery.IVTIntravenous thrombolysis.LFLow-frequency (0.07-0.2 Hz)LFOLow-frequency oscillationsLVOLarge-vessel OcclusionM1First part of middle cerebral artery.M2Second part of middle cerebral artery.MCAMiddle Cerebral ArterymRSmodified Rankin ScalemTICIModified Treatment In Cerebral InfarctionNIHSSNational Institutes of Health Stroke ScaleNIRSNear-Infrared SpectroscopyOxyHbOxygenated Hemoglobin ConcentrationPC-ASPECTSPosterior circulation Alberta Stroke Program Early CT ScorePCAPosterior cerebral artery.POSTSecond time segment (after achieving final reperfusion status)PREFirst time segment (after sedation but before any attempted revascularization)PSDPower spectralSTROBESTrengthening the Reporting of OBservational studies in EpidemiologyTFATransfer Function AnalysisTIATransient ischemic attackVLFVery low-frequency (0.02-0.07 Hz).VMCAFlow velocity in the Middle Cerebral Artery